Novo Nordisk’s products available on Hims & Hers. (Hims & Hers)

Novo Nordisk products available on Hims & Hers (Hims & Hers)

Hims reports revenue miss and surprise loss in Q1 after weight-loss drug shake-up

The company reported earnings results on Monday.

5/11/26 4:17PM

Hims & Hers fell in after-hours trading after it reported a surprise loss and revenue numbers that missed Wall Street expectations as its shift away from knockoff weight-loss drugs weighs on its margins.

For the first three months of 2026, the company reported:

$608 million in revenue, compared to the $616.8 million analysts polled by FactSet were expecting.
A loss per share of $0.40, compared to an expected profit of $0.03. Hims saw its margins shrink this quarter and also faced several one-time costs. Hims CFO Yemi Okupe told analysts he expects the company to return to profitability in 2027.

For the full year in 2026, the company expects:

Revenue to hit between $2.8 billion and $3.0 billion, higher than its previous guidance of $2.7 billion to $2.9 billion and in line with the $2.7 billion analysts are penciling in.
Adjusted EBITDA between $275 million and $350 million, higher than its previous forecast of $300 million to $375 million with a lower midpoint than the $317 million analysts are expecting.

The earnings report covers a very dramatic period for the company.

In February, the company rolled out a copy of Novo Nordisk’s Wegovy pill, which it eventually pulled after being sued by the drugmaker and getting scrutiny from regulators. It now partners with Novo to distribute its branded GLP-1s in exchange for dropping its cheaper, higher-margin knockoffs. CEO Andrew Dudum told analysts that the company had sent 125,000 shipments for Wegovy products so far.

Hims spent $33 million on that restructuring, which “consists of inventory write-downs and third-party costs,” the company said. Hims also said it spent $15 million in the quarter on “legal settlement costs.”

The company has gained a tailwind in recent months after the Food and Drug Administration announced that it would ease restrictions on 12 peptides, which Hims and other consumer health companies are eager to get in on. Dudum didn’t give a firm timeline on rolling out that segment but said, “We likely won’t be first to market.”

Executives put focus on its newer segments, such as hormone treatments, as well as its growing international presence. The company said its testosterone segment is now serving “tens of thousands” of people.

Luke Kawa

7/13/26

Meet the newly public, Bezos-backed company that’s recreating the sun and stars

General Fusion CEO Greg Twinney spoke with Sherwood News from the Nasdaq during the stock’s first day of trading.

J. Edward Moreno7/7/26

SpaceX gets a wave of bullish ratings from Wall Street analysts

SpaceX received more than a dozen positive analyst calls on Tuesday — including from major Wall Street banks — as they initiate coverage on Elon Musk’s space and AI company.

SpaceX went public on June 12 at a $2.2 trillion valuation, the largest debut in history. While the company hasn’t yet posted a profit, it seems to have convinced Wall Street that it will get there and grow its valuation on the way.

Of the at least 17 analysts that gave a rating on Tuesday, all but one gave it a “buy” or “outperform” rating. MoffettNathanson was "neutral."

The ratings come as SpaceX joined the Nasdaq 100 index, a benchmark tech-heavy basket of companies that underpins millions of portfolios. The inclusion adds built-in demand for the stock from index funds and ETFs.

Still, SpaceX fell more than 5% on Tuesday amid a broader sell-off, and is currently effectively flat from its opening price of $150 a share.

Luke Kawa

7/2/26

US job growth falls far short of estimates in June; unemployment rate unexpectedly dips to 4.2%

Job growth was 57,000. Analysts foresaw job growth of 113,000; prediction markets were more optimistic, looking for job growth above 125,000 but below 150,000.

Floridians Seek Employment Opportunities At Job Fair In Sunrise

Luke Kawa

7/1/26

Meta surges on report it’s starting a cloud business to sell excess AI compute

The story of the hyperscalers in 2026 has largely been “the beatings will continue until the cash flow outlook improves;” this could help change the story for Meta. Or not.

Meta CEO Mark Zuckerberg visits U.S. Capitol for Senate meetings

Paige Oamek6/30/26

Nike sinks to lowest level since 2014 after warning of “challenged” sales environment in Q4 report

Did Nike do it?

Investors had a mixed reaction after the global sports apparel company reported its fourth quarter earnings on Tuesday after the bell. Shares initially rose 5% as Nike beat out Wall Street expectations amid a hefty tariff refund bonus. However, the stock then sank to its lowest level since August 2014 in postmarket trading.

Here are the Q4 numbers:

Revenue of $11.0 billion (estimate: $10.8 billion).
Adjusted earnings per share of $0.20 (estimate: $0.12).

Ahead of this report, Nike warned that results would be flattered by a one-time tariff refund (now estimated at roughly $0.52 per share for the bottom line). That gave the company an extra cushion in snapping its streak of seven quarters of year-over-year profit declines.

Over the past year, the company had been punished by tariffs on imported goods, stagnant consumer spending, and increasing competition from other footwear brands like New Balance, Adidas, and Hoka.

Outgoing CFO Matthew Friend deemed it an “increasingly challenging operating environment, where sell-through remains challenged.”

Hims reports revenue miss and surprise loss in Q1 after weight-loss drug shake-up

More Markets

SpaceX gets a wave of bullish ratings from Wall Street analysts

Nike sinks to lowest level since 2014 after warning of “challenged” sales environment in Q4 report

Latest Stories